Nevro Corp. (NVRO)
NYSE: NVRO · IEX Real-Time Price · USD
11.32
-0.30 (-2.58%)
At close: Apr 26, 2024, 4:00 PM
11.31
-0.01 (-0.09%)
After-hours: Apr 26, 2024, 7:59 PM EDT
Nevro Revenue
In the year 2023, Nevro had annual revenue of $425.17M with 4.63% growth. Revenue in the quarter ending December 31, 2023 was $116.18M with 2.05% year-over-year growth.
Revenue (ttm)
$425.17M
Revenue Growth
+4.63%
P/S Ratio
0.97
Revenue / Employee
$349,937
Employees
1,215
Market Cap
412.02M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 425.17M | 18.81M | 4.63% |
Dec 31, 2022 | 406.37M | 19.46M | 5.03% |
Dec 31, 2021 | 386.91M | 24.86M | 6.87% |
Dec 31, 2020 | 362.05M | -28.21M | -7.23% |
Dec 31, 2019 | 390.26M | 2.97M | 0.77% |
Dec 31, 2018 | 387.29M | 60.62M | 18.56% |
Dec 31, 2017 | 326.67M | 98.17M | 42.96% |
Dec 31, 2016 | 228.50M | 158.90M | 228.28% |
Dec 31, 2015 | 69.61M | 37.03M | 113.69% |
Dec 31, 2014 | 32.57M | 9.07M | 38.61% |
Dec 31, 2013 | 23.50M | 5.35M | 29.48% |
Dec 31, 2012 | 18.15M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Aveanna Healthcare Holdings | 1.90B |
PetIQ | 1.10B |
LifeMD | 152.55M |
Fulcrum Therapeutics | 2.81M |
IGM Biosciences | 2.13M |
Shattuck Labs | 1.66M |
NVRO News
- 10 days ago - Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024 - PRNewsWire
- 2 months ago - Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw - PRNewsWire
- 2 months ago - Nevro Enters Into Cooperation Agreement With Engaged Capital - PRNewsWire
- 2 months ago - Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results - PRNewsWire
- 3 months ago - Nevro Announces Consensus Statement Supporting High-Frequency (10 kHz) Spinal Cord Stimulation Therapy for Refractory Painful Diabetic Neuropathy - PRNewsWire
- 3 months ago - Nevro to Report Fourth-Quarter and Full-Year 2023 Financial Results and Host Conference Call on February 21, 2024 - PRNewsWire
- 3 months ago - Nevro Announces Positive Coverage Update from Carelon Healthcare for the Treatment of Painful Diabetic Neuropathy - PRNewsWire
- 3 months ago - Nevro to Highlight 25 Scientific Abstracts at 2024 North American Neuromodulation Society (NANS) Annual Meeting - PRNewsWire